Fidelity Investments
TXG icon

Fidelity Investments’s 10x Genomics TXG Stock Holding History

Fidelity Investments’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$676M Sell
17,629,266
-111,706
-0.6% -$2.93M 0.03% 443
2026
Q1 		$377M Buy
17,740,972
+5,823,490
+49% +$116M 0.02% 617
2025
Q4 		$194M Buy
11,917,482
+3,459,481
+41% +$52.3M 0.01% 876
2025
Q3 		$98.9M Sell
8,458,001
-538,403
-6% -$7.02M 0.01% 1187
2025
Q2 		$104M Sell
8,996,404
-896,735
-9% -$8.17M 0.01% 1102
2025
Q1 		$86.4M Sell
9,893,139
-3,561,295
-26% -$44.9M 0.01% 1151
2024
Q4 		$193M Buy
13,454,434
+86,455
+0.6% +$1.36M 0.01% 838
2024
Q3 		$302M Buy
13,367,979
+357,470
+3% +$7.39M 0.02% 664
2024
Q2 		$253M Buy
13,010,509
+81,260
+0.6% +$2.13M 0.02% 702
2024
Q1 		$485M Buy
12,929,249
+143,713
+1% +$6.31M 0.03% 465
2023
Q4 		$715M Buy
12,785,536
+118,538
+0.9% +$5.16M 0.06% 314
2023
Q3 		$523M Buy
12,666,998
+4,565,400
+56% +$237M 0.05% 372
2023
Q2 		$452M Buy
8,101,598
+3,729,304
+85% +$202M 0.04% 446
2023
Q1 		$244M Buy
4,372,294
+1,169,928
+37% +$54.6M 0.02% 633
2022
Q4 		$117M Sell
3,202,366
-509,836
-14% -$16.7M 0.01% 911
2022
Q3 		$106M Sell
3,712,202
-2,483,325
-40% -$94.6M 0.01% 936
2022
Q2 		$280M Buy
6,195,527
+2,070,318
+50% +$107M 0.03% 582
2022
Q1 		$314M Sell
4,125,209
-3,062,865
-43% -$268M 0.03% 614
2021
Q4 		$1.07B Sell
7,188,074
-1,177,765
-14% -$180M 0.08% 225
2021
Q3 		$1.22B Buy
8,365,839
+467,613
+6% +$80.3M 0.1% 173
2021
Q2 		$1.55B Sell
7,898,226
-1,843,937
-19% -$334M 0.12% 139
2021
Q1 		$1.76B Sell
9,742,163
-328,920
-3% -$56.8M 0.15% 118
2020
Q4 		$1.43B Buy
10,071,083
+1,484,389
+17% +$215M 0.13% 143
2020
Q3 		$1.07B Buy
8,586,694
+1,398,273
+19% +$147M 0.11% 167
2020
Q2 		$642M Buy
7,188,421
+3,996,052
+125% +$311M 0.07% 244
2020
Q1 		$199M Buy
3,192,369
+57,291
+2% +$4.47M 0.03% 505
2019
Q4 		$239M Buy
3,135,078
+385,217
+14% +$23.2M 0.03% 583
2019
Q3 		$139M Buy
+2,749,861
New +$152M 0.02% 758

Other funds holding TXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments's TXG Position: Q2 2026 in Review

Fidelity Investments reduced its 10x Genomics (TXG) stake by 0.63% in Q2 2026, selling an estimated $2.93M and leaving 17,629,266 shares worth $676M. The position accounts for 0.03% of the portfolio, ranked #443.

Fidelity Investments first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $1.76B in Q1 2021. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Fidelity Investments held 17,629,266 shares of 10x Genomics worth $676M as of Q2 2026.
  • Fidelity Investments sold 111,706 10x Genomics shares in Q2 2026, an estimated $2.93M.
  • 10x Genomics made up 0.03% of Fidelity Investments's portfolio in Q2 2026, its #443 holding.
  • Fidelity Investments first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Fidelity Investments's 10x Genomics position peaked at $1.76B in Q1 2021.
  • 391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.